2020
DOI: 10.15252/emmm.201911801
|View full text |Cite
|
Sign up to set email alerts
|

“Designer cytokines” targeting the tumor vasculature—think global and act local

Abstract: Tumor necrosis factor (TNF) was discovered in 1975 as a lipopolysaccharide‐induced serum factor that causes necrosis of tumors (Carswell et al, 1975). It was later found that TNF and cachectin, a factor causing wasting disease, were one and the same molecule (Beutler et al, 1985). Studies on the inflammatory activity of TNF have been translated into clinical success, namely blocking antibodies used to suppress autoimmune diseases. Research on TNF anti‐tumor activity, in contrast, has not yet resulted in a ther… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 9 publications
(7 reference statements)
0
2
0
Order By: Relevance
“…Theoretically, similar approaches inducing "immunological reaction towards connective tissue" could be applied to situations where scarring or fibrosis has ensued, and the breakage of the fibrosis is desirable without side effects in the rest of the body. Most recently, the technology to target powerful cytokines was further refined by generating novel "designer cytokines" that have reduced systemic toxicity to one afforded by the selective delivery to target organ [85,86]. Namely, these "designer cytokines", TNFα and interferon-γ (IFNγ) are delivered to the angiogenic vasculature by a separate vascular targeting domain [85].…”
Section: Systemically Administered Anti-fibrotic Molecule Car-decorinmentioning
confidence: 99%
See 1 more Smart Citation
“…Theoretically, similar approaches inducing "immunological reaction towards connective tissue" could be applied to situations where scarring or fibrosis has ensued, and the breakage of the fibrosis is desirable without side effects in the rest of the body. Most recently, the technology to target powerful cytokines was further refined by generating novel "designer cytokines" that have reduced systemic toxicity to one afforded by the selective delivery to target organ [85,86]. Namely, these "designer cytokines", TNFα and interferon-γ (IFNγ) are delivered to the angiogenic vasculature by a separate vascular targeting domain [85].…”
Section: Systemically Administered Anti-fibrotic Molecule Car-decorinmentioning
confidence: 99%
“…In addition to that, they have a mutated receptor binding site in the therapeutic molecule, i.e. TNFα and IFNγ, to reduce their biological activity [85,86]. The reduced biological activity, in turn, reduces the systemic toxicity of the molecules and makes them viable, tolerated and safe drug option for systemic administration.…”
Section: Systemically Administered Anti-fibrotic Molecule Car-decorinmentioning
confidence: 99%